

تسمى بـ هistiocytes

Histiocytes

EMid
Bologna
Darruti

What is Histiocytes??

they are tissue Macrophages that:
derived from Blood Monocytes @ following

BM derived Precursors
(precursor cells)

Blood Monocytes

(half life 71 hr)
then:

Migrate to tissues
to differentiate into
2 Types of Histiocytes

(F)

"Ag. Presenting cells"

Function

① phagocytosis
f^o 81

② Ag presentation
(via MHC II)
to sensitized
T-Cells only
(not Naive
nor Memory)

③ Cytokines
product:

IL₁
IFN- β
GM-CSF

[Cells that responsive
to chemotactic
stimuli & are
attracted to site
of inflammation]

Professional Phagocytes (Macrophages)

2 Types

Immature
Macrophages
(Inflammatory
Macrophages)

Resident
tissue
Macrophages

Dendritic cells (DC)

Epidermal

"LC"

Dermal:

↓
Dendrocytes

Cut. dendritic cells (Ag presenting cells)

(F) < Ag presentation
(+++)
± phagocytosis
to 3 T cell
Types

Epidermal
Langerhan's
Cells

S100
CD 1a
CD 207

Dermal dendritic
Cells

p. Dermal dendrocytes

• site: supra basal (2-8%
of Epid. cells)

• Morphology: - dendritic
- pale staining cytoplasm
- Convolutated Nucl
- chic cytoplasmic
granules called

Birbeck granules

(tennis
Racquet)

• Rod shapped e-
Terming Vesicular
dilatat - [tennis
Racquet]

- (only) in LC
± Hairy cell.
leuk. cells.

→ derived from CM
by endocytosis.

(Funct)

Ag presentat to

T Cells
Sensitized
Naive
Memory

How?? by (1). Ag endocytosis

(2). Ag processing (by lysosomal
enz)

(3). reexpressing Ag on surf.
bound to MHC II

• 2 Types:-

① Type I:-

• upper dermal
- Known function
- Factor IIIa +ve
- melanin
- Hemosid.
- phago-
cytosis
- Ag pres-
ent

② Type II:-

• lower dermal
- Unknown function
- CD 34 +ve

→ represent subdomains of
endoplasmic recycling compartment
& form at sites where protein
Langerin Accumulat

• Receptors of it:-

• MHC II
• FC IgG
• C3b

• CD 1 (role in Ag presentation)
• S100

→ efferent
Lymphatics

• S100

- - MCS → hyper pigmentation
- - LCs
- - Schwann cells.
- Interdigitating Cells.
- Undetermined cells.

• Factor XIIIa → Endothelial → (vascular)
→ Type I dermal dendrocytes (DF)

• CD34 :-

- Endothelial (vascular)
- Type II dermal dendrocytes (DFSP)
- Mast cells
- Stem cells

• CD45 : Common Leukocytes
Antigen.

Histiocytosis

Def: reactive or B⁹ Accumulation of Histiocytes in many organs. According to the type of infiltrating Histiocytes there are 2 Types of Histiocytosis

→ Langerhans: LCs infect.
→ Non Langerhan infect. by cells other than LCs

(LCH) Class I: Langerhans' cell histiocytosis (Histiocytosis X)

Non-cancerous ('reactive') increase in number of Langerhans' cells (histiocytes within the epidermis)

+ve: S100, CD1a, CD207, Birbeck grs. & langerin

- Letterer-Siwe disease < 2y
- Hand-Schuller-Christian disease 2-6y
- Eosinophilic granuloma 5-15 skin
- Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease) Bone

Class II: Non-Langerhans' cell histiocytosis.

Class IIa: Dermal dendritic cell histiocytosis (DDH)

Non-cancerous ('reactive') increase in number of non-Langerhans' cell histiocytes.

ch-BY:

-ve S100, CD1a, Birbeck grs.

+ve CD68, Factor XIIIa

Hist. Xanthogranulomatous react.

اطفال

- Dermatofibroma (DF) (+ve XIIIa)
- Juvenile xanthogranuloma (XG)
- Benign cephalic histiocytosis (BCH)
- Generalised eruptive histiocytoma
- Papular xanthogranuloma
- Erdheim-Chester disease
- Progressive nodular histiocytosis
- Solitary reticulohistiocytoma (Solitary Retic.)
- Xanthoma disseminatum

Class IIb: Non-Langerhans' cell, non-dermal dendritic cell histiocytosis

Reactive increase in number of (non-Langerhans' and non-dermal dendritic) histiocytes

CD68 (Macrophage)
MAC387 (immature Macrophage)
HAM56.

- Diffuse plane xanthomatosis
- Reticulohistiocytosis. (+ Grenz zone)
- Necrobiotic xanthogranuloma →
- Rosai-Dorfman disease (S100)
- Familial haemophagocytic lymphohistiocytosis
- Familial sea-blue histiocytosis
- Hereditary progressive mucinous histiocytosis

Class III: Malignant histiocytoses

Cancerous change in histiocytes

- Monocytic leukaemia
- Malignant histiocytosis
- True histiocytic lymphoma

Langerhan's Cell Histiocytosis

(LCH)

Histiocytosis
-x

Def. reactive condition in w cells with phenotype of Langerhan's cells Accumulate in various tissues causing damage.


Etiopathogenesis unknown but \pm :-

- ① Infect \leftarrow TB
HSV 8 (was found in large No of patients \rightarrow \uparrow LC & \downarrow Immunological Control of Histiocyte prolif.
- ② Immunological (IL17 \rightarrow fusion bet Giant cells & Lcs).
- ③ Malignancy: LCH cells are clonal cells.

General character:-

① Reactive conditions d.t infilt. by LCs-like cells called LCH cells

② all types are \rightarrow S100 +ve
 \rightarrow CD1a +ve & CD207 = langerin
 \rightarrow Birbeck grs (+ve)



prognosis
 \rightarrow early onset & 2/3
& multi system
affect \rightarrow Poorer prognosis.

definit:-
 ≥ 2 organs or organ systems.

Risky organs:-

[Spleen
Liver
Lung] Blood (Hemorrhagic) 5

Langerhan's Cell Histiocytosis:-

(Histiocytosis-X \rightarrow because Unknown AE)

1. Pesterer siwede (Acute disseminated) [LSD]

- Age < 2 Ys

الظاهر - **Cut.** : Crusted, purpuric Papules, Vesicles & Pustules at scalp & Groin

→ MM & Nail effect

gingivitis
loose teeth

paronychia
dystrophy

بالرئيس . **Systemic** :

- Bone : osteolytic bone lesions
- L.N : Lymphadenopathy
- Lung : Pulm infilt.
- Liver : HSM
- Blood : Anemia & thrombocytopenia


An infant with crusted purpuric papules + seborrheic-like eruption in the scalp and groin (effocal) should raise the suspicion of LCH

Prognosis :

- Good (Bg) : if only Bone affected.
- Bad (Mg) : if early onset, Visceral Affects (HSM, purpura, thrombocytopenia) & Nail affects (syst)

2. Hand-schuller christian (HSCD) (chr. Multifocal)

2-6 Ys



3. Hashimoto pitzker (Cong. Self Healing Reticulohist)

Birth or Infancy

Cut. only : disseminated reddish brown Nods. & plaques, ulcers, Atrophic dyspigment. scars.

Course : self limiting (8-24 ms) then \pm recur \rightarrow LSD.

4. Eosinophilic granuloma (Bg localized)

5-15 Ys

Bone only : osteolytic lesions at flat bones (Scalp Vault) \rightarrow \pm fracture

Course : Self limiting \rightarrow LSD or HSCD.

3 levels

- [1.] Histopathology (LM):**

In All types there are LCH cells w ch B γ .

• There are 3 Types of Reactions:

in Hashimoto
Pritzker:
LCH Cells +
multinucleated cells.
mid & upper
Dermis.

□ LSD

Proliferative Reaction

1. CH cells infilt. upper dermis & invade epid. in many areas.

Hand-Schüler

Xanthomatous ReacL

• copper
dermis → Foamy Histiocytes ✓

FB (++)
Touton (+) > multinucleated giant cells

Eos.
gyn. uloma

Granulom-
atous

extensive
infilt. of
LCH cells &
clusters of

Eosinophils Gran
cells

[2] Immunohistochemistry: Both LCs & LCH cells show

+ve \therefore S100

- CD12
- CD207 (Langerin)
- Birbeck grs.

• So How
to differential
??

CBC
 - FTS
 3MA \uparrow
 Time 0.5m
 XR MRT \rightarrow Other Times

NB on LCH

Adult LCH:

• rare

- AbNL presentation: Flexural & perianal psoriasiform
vesicular &
papulovesicular
Crusted lesions.

Malignant LCH:

[A] Langerhans Cell Lymphoma = Langerhans sarcoma لجبة

- Solitary, Lymphoma like Tm
- Poor prognosis
- Path. → a typical dendritic histiocytes.

W are +ve S100
Neurone specific
Enkephalin

[B] LSD with malignant outcome:

- Early onset < 2y.
 - Visceral involvement
 - Purpura & anemia.
 - Clonality & cytological atypia.
-

LCs	LCH Cells.
<ul style="list-style-type: none"> • have dendrites. • convoluted nucleus • Birbeck grs. (+++) • CD1a + • S100 • CD 207 (Langerin) 	<ul style="list-style-type: none"> • No dendrites (ovoid) • kidney shaped. • \pm birbeck grs (5%) • as LCs + • PNA (Peanut agglut.) • PLAP (placental ALK. ph.)

• Cause of death: Inf, Systemic affect, Haemo-
Phagocytosis.

Treatment of langerhans cell histiocytosis (review 2012)
Hyst. dis.

Single-system disease			Multisystem disease
Skin		Bone	
Children	Adults		
Observation or topical nitrogen mustard	Topical nitrogen mustard PUVA CO ₂ laser Thalidomide Isotretinoin	• Surgery • Glucocorticoid injections • Radiotherapy • Monochemotherapy (in multiple bone lesions)	• Monochemotherapy with vinblastine or etoposide, preceded or not by glucocorticoid administration • Nonresponders may be treated with polychemotherapy

• DD of LCH

[1] LSD:

- [SD
- [AD
- [Wiskott Aldrich
- [Darier
- [Hashimoto Pritzker
- [Sinus Histiocytosis
- [Hemophagocytic Syndrome

[2] HSCD


- Xanthoma disseminatum
- JXG.

Non Langerhan Cell Histiocytosis

Class IIa- Dermal dendritic Cell Hist.

- Juvenile Xanthogranuloma
- Papular Xanthoma
- Xanthoma Disseminatum.
- Benign Cephalic Histiocytosis (BCH)
- Generalized Eruptive Histiocytoma (GEH)
- progressive Nodular Histiocytosis
- Reticulo histiocytosis (Solitary type)
- Others
 - Erdheim
 - Dermatofibroma.

(7) JAG



Xanthoma:

- Papular
- disseminatum

• Reticul Histiocytosis (Giant Cell Retic.)

نقص!

Juvenile Xanthogranuloma (JXG) ❌

(Nevo Xanthoendothelioma)

The most Common Type of Histiocytosis (at all)

Age $\begin{cases} \text{90\% Childhood} \rightarrow M > F \\ \text{10\% Adulthood} \rightarrow M = F \end{cases}$ (So the term Juvenile is not Accurate).

it may affect:

Cut. Extracut.

Skin:

MM (rare) \rightarrow ulcerating nodules at lat. tongue & palate.

Eye

Lung

Liver

CNS

CVS

Testes.

Associations

Systemic organ

Cut. Manifestations: (80-90%) appear in the First year & usually Solitary lesions.

lesion: Dome-shaped, reddish-brown or yellow nodule usually affect the head & Neck (also \pm upper trunk & extremities) $\xrightarrow{\text{fate}}$ $\begin{cases} \text{Childhood } \frac{3-6}{\%} \rightarrow \text{resolves} \\ \text{Adult} \rightarrow \text{Scar, Pigm. more persistent} \end{cases}$

According to size of lesion it may be

Classified as:

Micronodular (papular): $< 1 \text{ cm}$ & Multiple ($< 1 \text{ cm}$)

Macronodular: $> 1 \text{ cm}$, single or few ($> 1 \text{ cm}$)

Giant: $> 2 \text{ cm}$.

Adult XG

Ch By:

Solitary
persistent.

Crynoform

Sign: JXG

affect the

Nose \rightarrow diffuse enlargement.

Clinical varieties:

Lichenoid

Keratotic

Pedunculated

Clustered

S.C

Plaque

Crynoform

in site

in lesion

Lips, Toe, Scrotum.


• Visceral Manifestations: the most common affected organs are: الداخلية

• Eye (<1%): Iris affects ^{don't choose this} glaucoma & Hyphema → Blindness.

Eye is the most common extra cut. organ affected

[Lung
Liver
CNS
CVS
Testes⁺⁺] → Cause of death (± Spont. Resolution)

[Triple Association:]




CALM
20% ass.
30% Leukemia

NB: JxG ass. \approx CALM \approx 20% $\xrightarrow{13\% \text{ risk}}$ Leukemia (Ch. Myelogenous)

JxG + NF1 $\xrightarrow{30 \text{ times} \uparrow \text{ risk of}}$ Leukemia

• Diagnosis (3 levels)




Treatment (Not needed as it's self limiting).

- Excision → For cosmetic reasons.
- Ocular lesions → Topical Cs.
- Systemic lesions →
 - Cs + Cyclosporine
 - Chemotherapy

NB Touton Giant Cell,

Wreathy arrangement of nuclei (ring) around ~~non~~ foamy cytoplasm (in center) & foamy cytop. outside the nuclei.



• Papular Xanthoma

- Generalized, yellowish, asymptomatic "small papular" skin lesions on face & head.

No → Coalescence of lesions.
→ Lipid Impairment
→ Visceral involvement
→ D.I.

in adults
MM is affected.

• Pathology: Foamy (Xanthomatized) Histiocytes

+
Touton Giant cells.

[NO-
Inflamm.
cells]

• Fate < Children: Spont. resolution at (1-5y) → dyke-like
Adults: Persist.

Xanthoma Disseminatum

(Montgomery Synd.)



- usually Male < 25y (but any age 2m-80y)

Triad of:

1. SKIN lesions

(50%)
2. MM lesions

3. D.I (40%)



↳ d.i.
hypothalamic
& pituitary
stalk affected
mild &
transient.

SKIN lesions: hundreds of Bilat., Symmetrical

yellow or reddish-brown Papules & (Plaques)
on Flexures, Face & Eye-lid → w ± Coalesce → Verrucous.

Course: may $\left\{ \begin{array}{l} \text{Resolve} \\ \text{persistent} \\ \text{progressive} \end{array} \right.$ [good prognosis except for Laryngeal Lesions]

NB: it may be ass. w MM; Here it will be presented by "Sclerotic Variant": Extensive Keloid like w Trunk, Abcl. & limbs.

HP: dermal Infil. w (Spindle) Histiocytes, Foamy Histiocytes, Touton Cell & other Inflamm. cells.

- HT:
1. Air-way $\xrightarrow{\text{obst.}}$ Radioth.
 2. Clotibrate (Cyclophosphamide) \rightarrow \rightarrow
 3. Excision, Cryo, IL & dermabrasion.

نوعی تر و لوینا


Histiocytes

EMed
B-1-gamma
Dermati

what is Histiocytes??

they are tissue macrophages that
derived from Blood Monocytes (a) following

BM derived promonocytes
(precursor cells)




Blood Monocytes

(half life 71 hr)
then:



Migrate to tissues
to differentiate into

2 Types of
Histiocytes



(F)

"Ag. Presenting
cell"



Dendritic cells (DC)

Epidermof

"LC"

Dermof:

↓
Dendrocytes

Professional Phagocytes (Macro-
phages)

2 Types



Immature
Macrophages
(Inflammatory
Macrophages)

Resident
Tissue
Macrophages

Func-1

① phagocytosis
phag

② Ag. presentat-
(via MHC II)
to sensitized
T-Cells only
(not Naive
nor Memory)

③ Cytokine
product:

IL-1
IFN- β
GM-CSF

[Cells that responsive
to chemotactic
stimuli & are
attracted to site
of inflamm.]

Cut. dendritic cells (Ag presenting cells)

(F) Ag present (+++)
± phagocytosis
To 3 T cell types

Epidermal
Langerhans
cell

Dermal dendritic
cell

Dermal dendrocytes

• Site: supra basol (2-8' of Epid. cells)

• Morphology: dendritic
• pale staining cytoplasm
• convoluted Nucl.
• clear cytoplasmic granules called

"Birbeck granules"

• Rod shaped & Terminal Vesicular dilatation [tennis Racquet]

only in LC
± hairy cell.
leuk. cells.

• derived from 1 CM by endocytosis.

Function

Ag presentation to

T Cells $\begin{cases} \text{Sensitized} \\ \text{Naive} \\ \text{Memory} \end{cases}$

How? by (1). Ag endocytosis

(2). Ag processing (by lysosomal enz.)

(3). reexpressing Ag on surf. bound to MHC-II

2 Types:

1. Type I:

• upper dermal

• Known Function

• Factor VIIIa + we

• melanin
• hemoglobin

phagocytosis
Ag present

2. Type II

• lower dermal

• Unknown Function

• CD34+

→ represent subdomains of endoplasmic recycling compartment & form at sites where protein Langerin accumulates.

Receptors of it:

• MHC II
• FC IgG
• C3b

• CD1 (role in Ag presentation)
• S100.

→ efferent Lymphatic

• S100

- MCS
- LCs
- Schwann Cells

[Interdigitating Cells
undetermined cells

• Factor XIII a

Endothelial

Type I dermal
dendrocytes

(DF)

• CD84:

- Endothelial
- Type II dermal dendrocytes
- Mast cells
- Stem cells

(DF-sp)

• CD45 Common Leukocyte
Antigen.

Histiocytosis

Def reactive or Mg Accumulation of Histiocytes in many organs. According to the Type of infiltrating Histiocytes there are 2 Types of Histiocytosis

Langerhans: LC infiltr.
Non Langerhans: infiltr. by (all other than LCs)

Class I: Langerhans' cell histiocytosis (Histiocytosis X)

Non-cancerous ('reactive') increase in number of Langerhans' cells (histiocytes within the epidermis)

+ve: S100, CD1a, ^{CD207} Langerin & Birbeck grs.

- Letterer-Siwe disease
- Hand-Schuller-Christian disease
- Eosinophilic granuloma
- Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease)

Class II: Non-Langerhans' cell histiocytosis.

Class IIa: Dermal dendritic cell histiocytosis

Non-cancerous ('reactive') increase in number of non-Langerhans' cell histiocytes.

Ch Bx:

-ve $\left\{ \begin{array}{l} S100 \\ CD1a \\ Birbeck grs. \\ CD68 \end{array} \right.$

+ve $\left\{ \begin{array}{l} Factor XIIIa \end{array} \right.$

Hist. xanthogranuloma react.

- Dermatofibroma (DF) (Giant cell)
- Juvenile xanthogranuloma (JXG)
- Benign cephalic histiocytosis (BCH)
- Generalised eruptive histiocytoma
- Papular xanthogranuloma
- Erdheim-Chester disease
- Progressive nodular histiocytosis
- Solitary reticulohistiocytoma (Solitary Retic.)
- Xanthoma disseminatum

Class IIb: Non-Langerhans' cell, non-dermal dendritic cell histiocytosis

Reactive increase in number of (non-Langerhans' and non-dermal dendritic) histiocytes

CD68 (Macrophage)
MAC 387 (immature Macrophage)
HAM 56

- Diffuse plane xanthomatosis
- Reticulohistiocytosis (+ Grenz zone)
- Necrobiotic xanthogranuloma
- Rosai-Dorfman disease (S100)
- Familial haemophagocytic lymphohistiocytosis
- Familial sea-blue histiocytosis
- Hereditary progressive mucinous histiocytosis

Class III: Malignant histiocytoses

Cancerous change in histiocytes

- Monocytic leukaemia
- Malignant histiocytosis
- True histiocytic lymphoma

Langerhans Cell Histiocytosis

(Histiocytosis X)

(LCH)

Def. reactive condition in w cells with phenotype of Langerhans cells. Accumulate in various tissues causing damage.

Etiopathogenesis unknown but ±:


- ① Infect → ^{TB} HSV 6 (was found in large no of patients → ++ LC & ↓ Immunological control of Histiocyte prolif.)
- ② Immunological (IL17 → Fusion bet Giant cells & LCs).
- ③ Malignancy: LCH cells are clonal cells

General character:

reactive conditions d.t infect. by LCs-like cells called LCH cells

all Types are
 { S100 +ve
 CD1a +ve & CD207
 Birbeck grs. (+ve) }

affect → ±



prognosis

early onset < 2% & multi system affect → Poorer prognosis.

definit:
≥ 2 organs or organ systems.

RISKY organs

- Spleen
- Liver
- Lung

Blood (BM) (Hematopoietic)

Langerhan's Cell Histiocytosis:

(Histiocytosis - X (See) p. 4)

1. Litterer Sire (Acute disseminated) [LSD]

Age < 2 y

prob. Cut. : Crusted, purpuric Papules, Vesicles & pustules at scalp & Groin

MM & Nail effect →
 ↓
 - gingivitis
 - loose teeth
 - Paronychia
 - Dystrophy


Systemic :
 - Bone : osteolytic bone lesions
 - L.N : Lymphadenopathy
 - Lung : Pulm infilt.
 - Liver : HSM
 - Blood : Anemia & thrombocytopenia

An infant with crusted purpuric papules + seborrheic-like eruption in the scalp and groin (e four should raise the suspicion of
 ↓
 LCH

Prognosis :
 - Good (Bg) : if only Bone affected
 - Bad (Mg) : if early onset, visceral affected (HSM, purpura, thrombocytopenia) & Nail effect

2. Hand-Schuller-Christian (HSCD) (Chr. Multifocal)

2-6 y



3. Hashimoto Pritzker (Cong. Self Healing) (is MP)

birth or infancy
Cut. only : disseminated reddish brown nodules & plaques → Atrophic dyspigment. scars.
Course : Self limiting (8-24 mo) then ± recur or → LSD.

4. Eosinophilic granuloma (Bg local) (Ed)

5-15 y.
Bone only : osteolytic lesions at flat bones (Scalp Vault) → ± Fracture.

Course : Self limiting → LSD or HSCD.

Benign Cephalic Histocytosis

(BCH)

2-12m
2-8y
No MM
Visceral
Ht
Tendon or
Giant cell

onset: 2-12m → resolve at: 2-8y

Cir, yellow-red Flat macules & papules
at Face & Neck (± → chest & trunk)
→ more flattening & Hyperpigment
resolve spont at (2-8y) but may
leave Hyperpigment.

No $\left\{ \begin{array}{l} \text{MM or} \\ \text{Visceral} \\ \text{Ht} \end{array} \right.$ affect (Case report DI).

Coma Shaped
Bodies

JXG
BCH

Diagnosis: Histocytes rich in Coma Shaped
Bodies (No tendon, nor Giant Cells)

Ht: Self-limiting.

(1) Progressive Nodular:

Lecithin
MM

Any age
Papules & Nodules $\left\{ \begin{array}{l} \text{sp. at face} \\ \text{teeth} \end{array} \right.$
persistent
± MM

(2) Generalized Eruptive Histio.

Adults.
papules only ± "dark blue"
resolve spont. ± e- $\left\{ \begin{array}{l} \text{dyspigment} \\ \text{Scar} \end{array} \right.$

(3) Papular Xanthoma

Older age

(HP)

(1) Prog. Nodular: (no effective Ht)

Early: Foamy & Scalloped Histocytes.

Late: Spindle shaped arranged
as in storiform pattern.

occasional Giant Cells.

(2) Generalized Eruptive:

Neither Foamy nor Giant
Cells.

... $\left\{ \begin{array}{l} \text{Eruptive} \\ \text{Xanthoma} \end{array} \right.$

Eruptive Xanthoma
(DD)

(1) Eruptive Xanthoma.

(2) Eruptive Xanthoma

(3) Papular "

(4) Progressive Nodular -
Histocyt.

(5) Generalized Eruptive Histocyt.

(6) disseminated variant
of BCH.

(7) Nodular.

No family Nor Giant Cells:

BCH

Generalized Eruptive.

Class II b Histiocytosis


(Non LCs, Non dermal dendritic
Histiocytosis)

- Reticulo histiocytosis
- Necrobiotic XG
- [• Diffuse plane Xanthoma
- Sinus Histiocytosis e Massive L.N
- Indeterminate Cell Histiocytosis.
- [• Familial hemophagocytic Lymphohistiocytosis
- Familial sea blue histiocytosis
- [• Hereditary Progressive Mucinos... Histiocytosis
(Hist. with Mucinos)
- Histiocytosis with Necrosis
- Indeterminate Cell Histiocytosis.

Px: per

- Multi Centric
- 2 Xanthomas — ^{NXG} Plane Xanth. (Nonulipenic)
- Sinus Histiocytosis.
- malakoplakia

Reticulohistiocytosis



- $M = F$
- Young adults
- Class IIa
- $F > M$
- 4th decade
- Class IIb

① Solitary Reticulohistiocytoma: جذري خفا جلد (2) Head + ...

- usually, single, < 1cm, yellow-red nodule on head → resolve spont.
- rarely: multiple without systemic effect

② MultiCentric RH: → Pentad (lipoid dermatoarthritis) { ⑤: Skin, Joint, MM, MG, Hyperlipid }


Associations:

1. Skin lesions: skin colored-red or brown nodules & papules mainly Acral.

① Juxta-articular, in proximity of affected joints; dorsal hands, Feet, extensor elbows

② Face: ear pinna (chil) & scalp
± Lennie fac

③ Nails: periungual chie "Coral bead" & nail dystrophy.



3. Polyarthritis

- Symmetric, Erosive & Multileting.
- Typically: affects Hands.

2. MM
oral, nasal, pharyngeal & ocular.

Spontaneous Resolute ± occur in 5-10y.
(L.F.F)
subtle form:
Flat macules & papules of dorsal hands
very similar to LM
Coral: جذري
Ear: pinna
Pentad -

5. Hyperlipidemia
(30%)

Auto immunity

L Systemic Vasculties

• +ve tuberculin test

↑ ER, IgG, fever, slow.

heart, Eye, Lung, GIT lesions,

DD of
Juxta-articular
Nodules

- MCRH
- R.A
- Sarcoidosis
- Xanthomas
- Gout

Histopathology

SKIN Synovial
 Biopsy.

• Grenz
Zone is
+ve

oncoytic
histiocytes.

(e pink long thin cytoplasm)

- Contain lipid
- +ve PAS.

+ Giant Cells +

Others:

Lymphocytes

Es.

- Plasma Cells

- Fibrosis
(otol lesions)

Cytosol

Ground glass
(Homogenous =
Non Foamy) &
• Eosinophilic.

Nuclei

. 1-12

arranged ← Central,
Peripheral or
Haphazard

Immuno hist.

- +ve Histocytes of ~~lysozyme~~ ^{Antitrypsin}
- Classical Monocyte / Macrophage

Markers are +ve: CD 68, HPA 56 & Mac 387

Factor XIII $\begin{cases} +ve & \text{in Solitary.} \\ -ve & \text{in Multicentric.} \end{cases}$

Treatment

• CS + Azathioprine

• Cyclophosphamide & CyH

- Recently: Etanercept / Anti-TNF α

- Necrobiotic Xanthogranuloma → see granulomas
- Diffuse plane Xanthoma → " Xanthomas

• Sinus Histiocytosis with Massive L-N (Rosai-Dorfman dis).

- usually affect children & young adults. (10-30) ↑
نقص المناعة
= نقص المناعة
(extranodal)
- Course: indolent, self limited & protracted course marked by remission & Exacerbation.

CIP = Nodal affect + Extranodal affect + Association:

- 90%
- Massive, bilateral, painless Cervical L-N (Chic)

• 40%

• Comment is the skin 10%

• Skin affect ± the only finding about L-N (Cut. Sinus Histiocytosis)

• CIP: red-brown, Xanthomatous Macules, Papules, Nodules
usually at Eye lid Major area.

- Fever
- ↑ ESR
- ↑ IgG (Hypergammaglobulinemia)
- ↑ Neut.
- "Immune dysfuncⁿ" (18%) [15%]

usually: anti-RBCs antibodies & Joint dis.

So Rosai-Dorfman Synd. ±:

- Nodal (From interdigitating Histiocytes)
- Cutaneous.

• Bad prognostic signs:

1. Autoimmunity.
2. disseminated Nodal dis.
3. Visceral aff.: renal or Lower RT involvement, Hepatic

Prognosis: 60% → Persist
20% → resolute
10% → die.

Diagnosis

Pathology

Biopsy
Nodal extra-nodal

Histiocytes + Inflamm. cells + Emperipolesis

- Cytoplasm: foamy
- Eos., Abundant
- Nucleus: Large vesicular
- Feathery border

- Lymphocytes
- plasma cells

Lymphophagocytosis

(Chic but not unique)

(phagocytosis of intact Lymphocytes & plasma cells by Histiocytes)

infiltrating Sinuses of L.N or dermis of skin.

Immunohistochemical

CD68, HAM 56 & Mac 387 (+ve)

+ve S100

CD1a -ve

DD → disease is Massive L.N:

- Lymphomas (H. & non H.)
- CLL
- Metastases
- Infectious L.N
- Kikuchi's dis: ?? [Histiocytic Necrotizing Lymphadenitis]

CIP: Fever + Tender Cervical L.N

Asian, young women.

Normal: WBCs, ESR & Hct.

Path: LN shows

Necrotic foci

Cellular population of large blastic Lymphocytes & Histiocytes.

Histiocytes engulfing Apoptotic...

Ht of Rosai-Dorfman

No Ht (Self-limiting)

indications: destructive, disseminated dis, physical compromise

Types: surgical, radio, CS, Alk/Abby Agents

thalidomide (±)

Vincristine
Vincblastine

SP18

Indeterminate Cell Histiocytosis

(LCH & non LCH بعض الحالات)

• Children & Adults.

• Self limiting

• CIP < Generalized : GEH like
Solitary : single, soft, erythem. lesions } Ulcerated
± occur.

• rare : ocular & visceral affect

• path : as LCH (vacuolated / xanthomatized
Histiocytes throughout ! dermis)

• Immunohist :
+ve CD1a, S100
+ve CD68, HAM56 & Mac387.
-ve Birbeck granules.

• itt (not required as it self limited)

(+) • PUVA

• Chlordeoxyadenosine.

Familial hemophagocytic lymphohistiocytosis

- AR
- death in 12 mo
- wide spread infilt. of many organs by Lymphocytes & histiocytes showing prominent Cytophagocytosis.
- CIP
 - Fever
 - URTI
 - UGITI
 - Immunological abnormalities
 - Non specific Maculopapular rash.
 - hypercytokinemia: ↑ IFN γ - TNF- α , IL 6
- HT BM & Hemopoietic stem cell transplant.

Sea Blue Histiocytosis: inherited: rare skin Acquired: pigmented nodules

- \pm Familial inherited or Acquired.
- Chic: histiocyte cell contain cytoplasmic granules that stain (blue-green) ^(AZURE) ✓
Giemsa & blue with May-Grunwald stain
- these Histiocytes infilt. systemic organs & skin. \rightarrow
 - Papules
 - Eye lid swelling
 - Patchy gray pigm. of face & trunk.

inherited
Type \pm
ass. \dot{e} :
Neurological
abnormal.

Malakoplakia

- rare Immuno deficiency dis. of Macrophages. dit Abncl immune response to E. coli
- usually affect Urinary Bladder & \pm other sites \leftarrow GIT SKIN
- Cut. effect- is rare: perianal & perigenital Papules, nodules, plaques & Tms; Pink-Yellow \pm e central dimple or sinus
- HP: Hansmann Histiocytes: Histiocytes \dot{e} chic Michaelis-Guttman Bodies (Stain +ve for \leftarrow Cat \pm Iron & when fully developed \rightarrow like owl's eye).

+++

Surgery
 \rightarrow then
Antibiotics
(Sofrin)
Vit C
Clofazimine.

• Hereditary progressive Mucinous Histiocytosis

(Histiocytosis with Mucinosis)


- AD.
- Start in childhood (1st decade) & T.E. Age
- Skin Colored - red brown Nodules that affect
 - ↳ Nose
 - ↳ Hand,
 - ↳ Forearm,
 - ↳ thigh.
- path: Epithelioid & Spindle Shaped Histiocytes
- Mucin deposit (by Alcian or Toluidin Blue).
- No
 - ↳ Systemic affect
 - ↳ Spont. resolution
 - ↳ Ht.

• Histiocytosis + Necrosis = "Kikuchi dis"
(see DD of sinus histiocytosis) -

• Erdheim-Chester dis. (rare)

- Any age
- Cut Manif: Yellow nodules & indurated plaques at Periorbital, Trunk, scalp & Extremities.
- Systemic Manif:
 - DI
 - Bony lesions (Bone ache of legs)
 - Exophthalmos.
 - CNS, lung, adrenal, renal & testes.
- Death > 50%



Others:

- Melanocytic Nevi of Genital & Flexural skin
- Melanocytic Nevus of Acral skin.
- Recurrent Melanocytic Nevus (Pseudo-Melanoma)
- Pigmented Spindle Cell Nevus.

Melanocytic Nevi

2017

ألوان (Moles)

Def: Bg Neoplasms or Hamartomas Composed of

Type of MCs called Nevus Cells

2 Main differences bet
it. & NL MCs:

- ① present in Nests (NL MCs present singly)
- ② Has No dendrites (Except in Blue Nevi).
- ③ Doesn't deliver Melanin to surrounding KCs.



Nevus Cells Has 3 Types (ELN)

• Type A (Epithelioid like)

• in lower epid & upper dermis

• Epithelioid like (tall or large simulating epid. KCs)

Contain Considerable amount of melanin.

• Type B (Lymphocytoid)

• Mid dermis

• Lymphoid like (small lymphocytes)

• Very little or no melanin.

• Type C (Neuroid)

• Lower dermis

• Neuroid-like (Schwann cell like or fibroblast like)

Elongated & spindle nuclear.



• origin (Embryology) either:

① Dual origin: Nevus Cells of upper dermis originate from MCs
lower : Schwann Cells

② Single origin: From Neural Crest which gives neuroblast → Nevus Cells
Melanoblast → Leptomeninges, Uvea, Tract, Derm. & H&H
Schwann cell

• Rare Melani

(NAevus just
Nevus cell)

Classification of Melanocytic Nevi

(ONIN2)

- ① ACC to ! Age of onset : Congenital
Acquired
- ② Histopathological: Junctional, Dermal, Compound & Combined melanocytic.
- ③ Atypical & Typical.

① Classification of Melanocytic

Nevi acc. to ! Age of onset

Congenital (<2y)

Acquired (>2y)

True
Congenital

Congenital
like or

appears at
birth

Tardive Nev.
(develop in 2y
after birth)

Not at birth

usually: start at
childhood or early
adulthood (1st 3
decades)

• Types: (According to Size) (2013)

- Small < 1.5 cm diameter
- Medium: 1.5 - 10 cm
- Large: 10 - 20 cm
- Giant: > 20 cm
- Satellite

- Larger
- Elevated
- Dark
- ± Hair.

• HP Types: Compound

• Clinical Types:

1. Junctional: بقعة لائقة
2. Compound: بقعة وفاقية
3. Intradermal: بقعة لائقة
(skin color) وفاقية
وفاقية

• HP: Junctional, Compound & D.

• Difference bet Cong. & Acquired Nevi
by HP

• Cong. Nevi ch BY: Nesting of Nevus Cells:

Cong. Nevi

- Cong. Melanocytic N.
- Spilus Nevus
- CALM
- Ota.

- Extend deeply to deep dermis & S.C.T
- clusters around Adnexae & BVs
- infilt. bet collagen bundles.
- Nevus-cell poor subepid. zone.

طریقی مشہور ترین
نقص لہذا تعریف کلیہ طار

Acquired Nevus

CIP 1. Junctional Nevus

- Junctional prolif. of Nevus cells at DEJ
- Clinically: Just macular pigmentation (No elevation)

Nevus Cells are Epithelial like

نقطہ کثرت
Nevus cells

2. Compound Nevus

- Nevus cells proliferate both at DEJ & at dermis (upper)
- Nevus cells are lymphocytic like
- Slightly elevated (papule) Darkly pigmented.

3. Dermal Nevus

- Nevus cells proliferate at dermis (No Junctional Activity)
- Nevus cells are Neuronal like.
- Moderately elevated papule / Nodule e light or No pig.

The Nevus may start junctional → Compound or Intradermal
So Elevation is not a sign of Malignant Transformation in Cong. > Acq.

Congenital Melanocytic Nevus (CMN)


- Types according to size: Small < 1.5 cm diameter, Medium: 1.5-10 cm, Large: 11-20 cm & Giant > 20 cm.

Giant Cong. Melanocytic Nevus: (Bathing Trunk)

- 5% → Incid of MM (Compared to < 1% in other types)
- 10% → assoc. e Neurocut. Melanocytosis specially if large, Axial
- 80% → ± assoc e Satellites. A.S. e Satellite

نوروت. ملانوسس (NCM) = Neurocut. Melanosis

Def. either Cong. Bathing Trunk (Giant) or Small, Medium sized "Satellites"



- Complications
- 1) disfigurement
 - 2) MG
 - 4) dryness & itching ↓ seb. & sweat glands

of Cong. melanocytic Nevus: Surgery; or other times (Laser, shave) are assoc. with Recurrence

Halo-Nevus

(Sutton's Nevus = Perineurid Vitiligo = leukoderma
Acquisitum Centriguum) (LAC)

Epidemiology:

Age usually < 20y. (usually Acquired)

Associat.
 Common: Vitiligo (20%) & other halo nevus (25-50%)
 Less: atypical Nevus & Melanoma.

Course
 Halo: occurs over period of wks - mos.
 Nevus:
 → occasionally persist → then repigmentation of Halo
 → More likely involute (wks - mos) → persistence of Halo for mos - yrs (or may ↓)

theory of development of the Halo

2 theories:

(Now favored)

① Immune response against antigenically altered Nevus cells ass. \bar{E} Tm progression: Comp?

Atypical Nevus \xrightarrow{Se} Immunologic response ass. \bar{E} Tumorigenesis

Atypical Nevus \xrightarrow{Se} Immunologic response ass. \bar{E} Tumorigenesis

② CMI & HI against non specifically altered Neve melanocytes & possible CMI reactivity \bar{E} distant Neve melanocytes

CIP * Nevus: Typical brown or dark, flat or raised \bar{E} surface scaling or crusting.

its Acquired Melanocytic Nevus

Typical Mean

- . A
- . B
- . C
- . D

3-6 mm (largest diameter)
regular well defined border
Homogeneous color.
Symmetrical

* Halo: start as erythema → Hypo or depigment.
(May be Examined in WL) [Symmetrical in Width]

Types of Halo Nevus

1. Inflammatory

- +ve infilt. by HP
- ماتعة لوانا

2. Non-Inflammatory:

- ve Infilt.
- ماتعة

3. Halo Nevus without Halo

- +ve infilt.
- Clinically: No Halo.

DD — Halo Dermatitis (ECZ.)
— Halo depigment:

Melanocytic
proliferation
in Halo

By
Atypical
MM
Blue
Spitz

- Cong. Nevi
- Atypical Nevi
- blue nevi
- Spitz Nevi
- Melanoma &
Melanoma Metastases.
(Asym. Halo)


Non Melanocytic
lesions in Halo

- DF
- SK
- plane warts
- Molluscum
- BCC.
- L.P.
- Psoriasis
- Sarcomas

Treatment

- All cases look for
- 1) other Halo nevi (25%-50%)
 - 2) Vitiligo (20%)
 - 3) Atypical Nevi
 - 4) Melanoma (or history of FH)

Any pt > 40y. Ⓢ Multiple Halo nevi → examine for Melanoma (ocular &c)



نیل

Dermal Melanocytosis (Dermal Melanocytic Nevus Ceruleoderma)

Pathophysiology

due to arrest of MC Migration
from dermis to epid → dendritic
& (Fusiform) MCs.

due To optical effect (Tyndall Phenom.)
→ ^{vis} Slate-brown or blue-black or
Ceruleoderma

Types: (یافته)

1. Mongolian Spots.
2. Nevus of Ota
3. Nevus of Ito
4. Blue Nevus.

① Mongolian Spot

onset: at birth or 1st week,
rarely childhood → regresses in
childhood.

Etiopathogenesis - MCs reach dermis at birth
then either migrate to epid. or die
Except at Scalp
extensor distal extremities.
Sacral area.

ساق و بازو ↓

(Slate الفسفوری)
نقد دراز آجری

why appears blue ?? Tyndall phenomenon
or Slate-brown
(Ceruleoderma)

Def. ↓ reflectance in! longer wave length region compared to the surrounding skin

- longer wave-lengths: as: red, orange, yellow
- shorter " " as: blue & violet → reflected

CIP

Most Common Sites:

- Sacroccygeal
 - Lumbar
 - buttocks
 - back
- extra sacral variant
(Aberrant variant) →
More persistent.

Q13. Extensive lesions $\xrightarrow{2}$ Phakomatosis pigmentosa vascularis Types II & IV

Treatment

1. Reassurance; self limiting
2. Laser

Nevus of Ota (Oculodermal melanocytosis)

At birth (50%) or Acquired (around puberty)

80% are females

May affect

SKIN: at distrib. of Trigeminal Nerve
bros (Facial)

EYE: sclera → iris mottled (but no visual affect) or Glaucoma

MM: Nasal Mucosa.

العين (eye) → Take Care of Eye as:

(Glaucoma, etc.)

- Glaucoma
- Melanoma (most melanomas are ocular)

Bilateral Variant is called Nevus of Hori:

العين (eye)
unilat. Nevus of Ota

- ♀ 20-70y.
- at Zygoma
- no ocular or nasal effect
- ± mis diagnosed as Melasma

Nevus of Ito

as Ota Nevus but differs in its distribution at Shoulder & upper arm
as Ito's is at ant. supraclavicular & lat. brachial cut.

Blue Nevus (& its variants)

• onset: Acquired (Childhood or adulthood) → rarely Congenital.

• Etiopathogenesis:
Dermis, MC, Epidermis
Site of Blue Nevus.

~ordinary~

• Types: (1) Common Blue Nevus: (0.5-1 cm.)

• Blue or blue-black papule < 1 cm
usually at dorsal Hands & feet. (± face & scalp)

• path: NL MCs singly or in nests in dermis
& periappendageal.

(2) Cellular Blue Nevus: [May → MM]

• Nodule or plaque ≥ 1-3 cm.

• Buttock, Scalp > Extremities & Face.

(3) Mj Blue Nevus: [Cut. Melanoma arising (in)
or having features of
Blue Nevus].

• Cut. Melanoma arise on top of any Blue
Nevus or develops de novo

• Large, multilobulated plaque at scalp.

• DD: Conditions Simulating Blue Nevus: Traumatic tattoo, Compound Nevus,
DF, Venous lake, Pigmented BC

Treatment:

(1) if: < 1 cm, stable & No features of Mj & in
typical sites → No Hx

(2) if: large, progressive, multinodular or plaque
→ Excision. (Mj melanoma)

(2012)

Spitz Nevus

Melanoma and Spitz Nevus



(Epithelioid & Spindle cell Nevus / Benign Juvenile Melanoma)

Type of Congenital

Def: Sp Nevus affects children & resembles Malignant Melanoma both Clinically & Pathologically

Etiopath. May develop de novo or on top of existing Melanocytic Nevus.

Epidemiology: Age: 50% < 10y & 70% → 2nd decade (Etiology)

Sex: M = F.

Race: Fair skin.

(d.t excess vascularity & minor pigm)

CIP: Single, dome shaped red or pigmented papule or nodule usually on legs & face (in adult → any site)

the lesion: shows rapid growth (1cm in 6ms)

then → static for years but often disappear spontaneously

Clinical Varieties

1. The lesion is:

- Polypoid.
- Crusted.
- Telangiect.

2. Multiple:

- Agminated = grouped
- Disseminated

3. Atypical

4. Mg = Spitzoid Melanoma.

HP

appi: Nests of Epithelioid & Spindle cell shaped MCs

arranged in clusters & Giant multinucleated Nevus cell among them.

↓
Vertical Fascicular (bundles) arrangement.

+

Kamino Bodies: Eosinophilic, PAS +ve Globules Among Nests (degenerated KC)

HT: Surgical Excision.

.. A typical / Dysplastic Nevus = Clark's Nevus

Def: Acquired compound Nevus whose clinical & histological definitions are controversial & still evolving

- Etiopath: ① Idiopathic (Sporadic)
 ② Familial (Genetic)
 ③ UVE
- Types: ① Sporadic ← Any Age:
 1-10 lesions
 Risk: 6%
 FAMM

② Familial ← Isi-de cadai
 10-100 lesions
 Risk (Cumulative) (100%)

was previously named « Dysplastic

Nevus Synd » now called

Familial Atypical Mole &
 Melanoma (FAMM) Synd

Criteria For D:

- (i). FH of malign melanoma
 (of 1st or 2nd degree relative)
- (ii). > 50 Nevi Some of w
 are clinically atypical.
- (iii). Dysplastic Histopath.

HP

Odd looking Atypical

MCs ← Epithelial (End KG)
 Spindle shaped
 (Elongated)

Proliferate singly & in
 Nests at DEJ & dermis
 (nequus) & may bridge
 or join Together

2 Fibrosis, Bv, Infil.

① 1st degree relative: "Excise"
 if Mq → Excision.

	Common Acq. Nevus (Benign)	Atypical Nevus	Melanoma
Asymmetry	Mirror Image Symmetry	Some Asymmetry	Asymmetrical
Border	Regular & Well defined	Irreg. & ill defined (not scalloped or Notched)	Very ^{irreg.} ill defined (scalloped or Notched)
Color	Homogeneous regularity. (tan - dark brown or skin colored)	Some what haphazard (irregularity of pig.) 2-3 colors [tan, brown, dark brown] But (+) gray, blue, white	Haphazard (more complexity)
Diameter	< 5 - 6 mm (< 5)	3 - 15 mm (> 5)	any but usually > 5mm

Malignant Melanoma (MM)

Def Neoplasm of Melanocytic origin that begins as prolif. of Atypical MCs at DEJ. Then by Time → Invade Dermis & S.C.T → ± Lymphatic & Blood spread.

Age : . usually > 60 y.
 . rare in prepubertals
 . in children usually arise { on Top of Giant or Cong Abnormal Nevi (ACq.)
 Transplacental Spread from the affected mother (Cong. MM)

Incid : . highest rate in Whites (30-37 / 100,000)
 . Mortality : . 75% of deaths from Cancer is MM
 . أكثر شيوعاً بين البيض
في سن 30-37 (5.12) في 100,000

Risk Factors: ① Fair Complexion (skin I & II)

chr. ② UVL Exposure

③ precursor nevi (pre Mg)

Dysplastic Nev. (FAMM)

Numerous Atypical Nevi

Giant Nevi

(>5)

④ Past Hx or Family Hx of MM

⑤ Genetic Mutations. (Cered. - v. w. 12)



70% of MM develop on Top of NL SKIN

NB Small-medium sized Cong. Nevi 1% → MM
 Giant bathing Trunk 5-10% → MM

other organs can be affected by MM (sites of MCs)


Orbit	Vulvae	Eye
Oral & nasal cavity	Vagina	Ear
Meninges	Urethra	

Types ④ Main Clinicopathological Types + others (HL)



- What is the :
 - Commonest type ?? & rarest Type
 - best prognosis ??

Σ



* Histology of the different types of melanoma.

General CIP of MM

Has 2 Clinical/Pathological
Stages

↓
Early stage or lesion:

- Clinically: Hyperpigmented Macule/Patch that shows ABCDE &/or Glasgow 7-point checklist Criteria.

↓
Late stage

- Clinically: Pigmented Nodule (± non-pigmented)
- Pathologically: Dermal Invasion by M_g. Melanocytes [late Vertical growth phase]

- Pathologically: M_g prolif. of Melanocytes in Horizontal direction at BMZ (in situ) without dermal Invasion [Early radial growth Phase]

MM usually asympt.; but ± itchy or Tender (A_{LM})

The ABCDE of melanoma

A	Asymmetry (2 halves of the lesions are not symm.)
B	Border irregularity (<u>edge</u> : ragged, Notched or Blurred)
C	Colour variation (<u>not</u> uniform; ± أصفر - أبيض - أحمر - بني - أسود)
D	Diameter over 6 mm
E	Evolving . Dramatic changes in Size & Shape.

Glasgow 7-point checklist

Major features	Minor features
<ul style="list-style-type: none"> Change in size Irregular shape Variable colour 	<ul style="list-style-type: none"> Diameter > 7mm . Inflammation Oozing Change in sensation

Discussion of Each Type

lentigenes →
ABCDs change
→ called lentigo-
maligna (in situ
MM) → LMM
(Invasive).

• LMM

• Incid, Age, Site as before.

• Site: Face sp. Cheeks & ears (skin around HF).

• on Top of sun damage skin (on Top of Lentigenes)

• Progression to invasive MM ≈ 5% (Macule → Nodule)

• CIP (see [1]) — Early Macular radial growth phase (± ABCD Glasgow) — Late Nodular Vertical " " "

• Varieties: Desmoplastic - Neurotropic - Myxoid

• ALM:

• Incid: Commonest Type in Blacks 50% (10% in whites)

• Age! —

• Site: Acral — Palms (on digits & w.t. bearing Heels) — Soles (Bed & perungual) — Nails

→ "gloabrous skin"

→ Melanonychia e + ve
Hutchinson
sign

→ Tender
plantar
Nodule

• CIP: see [1]

→ Biopsy

• Nodular M:

• Starts as Nodular radial growth stage
(No Macular radial growth phase)

• Incid, age, Site → as before.
Gany ✓

• Varieties:

• Classical lesion (Pigmented Nodule)

• Ulcerated "

• Amelanotic

• Non pigmented Nodule (DD ← BCC PG Poroma)

• the Classical lesion in Albinics.

• SMM: → see [1]

• Other Variants of MM

(1) Ocular MM : e. Nevus of Ota

(2) Mucosal : mouth, Nasopharynx, Larynx, Vagina & Anus.

(3) Nevoid Melanoma : No epid. involvement.

(4) HP Variants:

- Desmoplastic → fibrous stroma
- Neurotropic → perineural invasion → Pain
- Myxoid → Myxoid Stroma.

(5) Animal type : "Haxi" (حيوانية)

(6) Spitzoid

(7) Blue

• Hutchinson Sign : subungual Melanoma with extension of Pigmentation To Lat & proximal Nail Fold.



• Pseudo Hutchinson sign : ليس القرفصاء مش بيتحل
Benign EMU, Melanoma مع Condition.

• Hutchinson in Dermatology ??



Diagnosis of MM

(For) Melanoma
L.N
Metast.

- ① Clinical — ABCDE
Glasgow - 7 point check list.
- ② Dermoscopy
- ③ HP & Immunohistochemistry
- ④ SLNB (Sentinel L.N Biopsy)
- ⑤ Metastatic work up.
- ⑥ Staging of MM

HP

① LMM

- Junctional prolif. of Atypical (M₂) spindle shaped MCs → dermal nests.
- Adnexal involvement
- Solar Elastosis
- Lymphocytic infl.
- little Pagetoid scatters.

② ALM: → Epidermis show: as LMM +

• Hyperplastic

• Pagetoid scatter: Atypical MCs present singly (most common) or in an irregular shaped nests at all levels of Epid.

No/Little
Pagetoid → LMM
ALM
+ve Pagetoid → SMM

③ Nodular M: (no radial growth)



dermal invasion that connect immediately to overlying Epid. NO morphologic abnormality in adjacent epid. on either side of 1 nodule.

④ Superficial spreading (Pagetoid Melanoma):

Wedge
BUCKSHOT
Pattern.

dermal nests = Atypical cells in suprabasal layer of epid. (singly or in clumps) → simulating EMPD.

→ Nerve up severe pain.

⑤ Desmoplastic, Neurotropic & Myxoid: 3 variants of LMM describing the stroma surrounding the nest.

⑥ Nevoid (Small cell Melanoma): No epid. Affects = dermal invasion by Nevoid cells.


Streak
horser. ⑦ Animal Type: Blue-Black Nodule = sheets of Atypical spindle cells & Heavy dermal Melanin.

لازم تقدير الباثولوجي عامل تعليق على هذه النقاط

- Diagnosis (تشخيص)
- Breslow Thickness (depth)
- Clark's Level of Invasion
- Lympho, vascular or Neural Invasion, ulcerate
- Mitoses
- Margins.

1- Breslow thickness


The Breslow thickness is reported for invasive melanomas. It is measured vertically in millimetres from the top of the granular layer (or base of superficial ulceration) to the deepest point of tumour involvement. It is a strong predictor of outcome; the thicker the melanoma, the more likely it is to metastasise (spread). (5)



2- Clark's level of invasion (5)

Level 1	In situ melanoma
Level 2	Melanoma has invaded papillary dermis
Level 3	Melanoma has filled papillary dermis
Level 4	Melanoma has invaded reticular dermis
Level 5	Melanoma has invaded subcutaneous tissue

The deeper the Clark level, the greater the risk of metastasis (secondary spread). It is useful in predicting outcome in thin tumours, and less useful for thicker ones in comparison to the value of the Breslow thickness.



* Schematic representation of Breslow's and Clark's methods of microstaging malignant melanoma.

• Immunohistology (Immunohistochemistry)

ایم یو ای

• S100 (Ca binding protein):

- Very sensitive for MCs & Melanoma
- Most reliable for Identifying Spindled M.
- NB: expressed also at: nerve cells & Langerhans' Cell

• HM B45/gp100:

- Melanosome Specific Glycoprotein gp100.
- Specific for MC & Nevus cells.
- of limited benefit ?? false -ve (35%) & Heterogeneous staining pattern.

• Melan-A / MART-1:

• Tyrosinase

]- of limited sensitivity

③ SLNB: (H) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100)

done for staging of regional L-N

Indication: ① Breslow depth ≥ 1 mm

② presence of $\left\{ \begin{array}{l} ulcerated- \\ lymphovascular \text{ Invasion} \\ \text{High Mitoses} \end{array} \right.$

Nodal Metastases positive for mic 25 & 2. (100)

N2c

- ① dermal / s.c. Lymphatics \bar{e} in ≤ 2 cm from the 1ry Tm \rightarrow Called "Satellite Metastases"
- ② dermal / s.c. Lymphatics \bar{e} in > 2 cm from the 1ry Tm but not beyond the region of L-N \rightarrow Called "In Transit Metastases"
- ③ Regional L-N metastases \bar{e} may be Macro-Metastases (causing clinical Enlargement) or Micro Metast. CLN clinically NL but Histological involve

4. Metastatic Work up.

Indication (2S) ① Breslow depth / Thickness ≥ 4 mm

② presence of: ulcerated or lymphovascular Inv.

③ +ve SLNB

④ symptomatic patient $\left\{ \begin{array}{l} \text{depth} > 4 \text{ mm} \\ \text{stage} > \text{IIc} \end{array} \right.$

Inv.

CXR

LDH

CT / MRI

Others: PET, PCR, S100, HMB-45.

Marker of stage IV

Serum = Marker of Metast.

⑤ Staging of mm

تہ طریقہ سسٹم درجہ

3- American Joint Committee on Cancer (AJCC) cutaneous melanoma staging guidelines (2009).

Stage	Characteristics
Stage 0	In situ melanoma
Stage 1	Thin melanoma <2 mm in thickness
Stage 2	Thick melanoma > 2 mm in thickness
Stage 3	Melanoma spread to involve local lymph nodes
Stage 4	Distant metastases have been detected

N
M

ان طریقہ سسٹم بالاطع لایندہ درجہ

Stage	TNM Classification	Histologic/Clinical Features	5-Year Survival Rate, %
0	Tis N0 M0	Intraepithelial/in situ melanoma	100
IA	T1a N0 M0	≤1 mm without ulceration and mitotic rate < 1/mm ²	97
IB	T1b N0 M0	≤1 mm with ulceration or mitotic rate ≥1/mm ²	91-94
	T2a N0 M0	1.01-2 mm without ulceration	
IIA	T2b N0 M0	1.01-2 mm with ulceration	79-82
	T3a N0 M0	2.01-4 mm without ulceration	
IIIB	T3b N0 M0	2.01-4 mm with ulceration	68-71
	T4a N0 M0	4 mm without ulceration	
IIIC	T4b N0 M0	>4 mm with ulceration	53
IIIA	T1-4a N1a M0	Single regional nodal micrometastasis, nonulcerated primary	78
	T1-4a N2a M0	2-3 microscopic positive regional nodes, nonulcerated primary	
IIIB	T1-4b N1a M0	Single regional nodal micrometastasis, ulcerated primary	54-59
	T1-4b N2a M0	2-3 microscopic regional nodes, nonulcerated primary	
	T1-4a N1b M0	Single regional nodal macrometastasis, nonulcerated primary	
	T1-4a N2b M0	2-3 macroscopic regional nodes, no ulceration of primary	
	T1-4a/b N2c M0	In-transit met(s)* and/or satellite lesion(s) without metastatic lymph nodes	
IIIC	T1-4b N2a M0	Single macroscopic regional node, ulcerated primary	40
	T1-4b N2b M0	2-3 macroscopic metastatic regional nodes, ulcerated primary	
	Any T N3 M0	4 or more metastatic nodes, matted nodes/gross extracapsular extension, or in-transit met(s)/satellite lesion(s) and metastatic nodes	
IV	Any T any N M1a	Distant skin, subcutaneous, or nodal mets with normal LDH levels	< 20
	Any T any N M1b	Lung mets with normal LDH	
	Any T any N M1c	All other visceral mets with normal LDH or any distant mets with elevated LDH	

lines of Treatment of MM (bep 3)

(Emed)
2cl 2

بب ٢ ٤ ٥

Surgical Excision

only Surgical
Excision & Safety
Margin: for melanoma
≤ 1 mm depth & No-
ulceration, Lympho Vasc.
Invasion & low mitoses.

Excision
+
LND (SLND)

For Tms:

- (i) ≥ 1 mm depth
- (ii) ulceration, Lympho-
Vasc. invasion,
Mitotic rate $\geq 1/\text{mm}^2$

Excision
+
SLND

Adjuvant IT

indication

Stage II B, II C & III

Stage: III & IV

• IFN-α 2b (FDA)

- Chemotherapy: IFN α 2b
- Immunotherapy: Ipilimumab, GM-CSF, Vaccines
- Radiotherapy
- Retinoid Therapy
- Vitamins

Recent Treatments

Melanoma Vaccines:

خبرة (٢٠٠٢) بـ (٢٠٠٢) تقديم خلايا أو
مستقلات أو سطح MM بـ (٢٠٠٢) بـ (٢٠٠٢)
التي فتحت (٢٠٠٢) ع

Certain HLA & Tm. Ass Ag

→ ++ NK & HI → Kill melanoma cells

little S.E as compared to other Adjuvants.

الدكترة
عمرها بالتفصيل

BRAF Inhibitors

Vemurafenib (FDA 2cl)

Melanomas show
Mutations in certain proteins
as BRAF & NRAS →
so Inhibition of these
mutated proteins →
treat MM.

BRAF Genes are Proto-onc

1. Try Melanoma H

2 H of Regional Metast Melanoma

(A) LN dissect

Excision & Safety Margin
depends on Breslow's depth:

جراحيا
(JAD)

SURGICAL TREATMENT OF PRIMARY		
Thickness	Excision margins (cm)	
In-situ	0.5	
<1 mm	1.0	
1-4 mm	2.0 + SLND	
>4 mm	2.0-3.0 + SLND + Adjuvant	

Management of Regional
(L-N)

ELND (Elective L-N dissect)

Excision of clinically or
rad. NL draining L.N
(No improvement in
Survival rate & Carry

RISK of Complication
(Hematoma
Lymphaden-
disturb Imm.
again MM)

only
NB
20% of pt & Tm > 1mm
eaf evidence of Metast.
(Clinically or radically) →
Show Micro Metastasis.

Technique
Sot &

SLND (Selective LND or Sentinel LND)

Blue dye is injected
ID at Tm site →
initially drain to
specific Node(s)
called Sentinel (1-2)
Nodes

Biopsied (SLNB)
Biopsy

+ve Tm
Cells

Complete L-Node
dissect (Sentinel
or Selective
Lymphadenectomy)

&
Further Staging

-ve Tm
Cells

No further
Surgery.

SLND

less Traumatic
ELND (because
20% Show Micro

Lymphoscintigram
تصوير دقة (علا) ليدون
NL بعد حقن
SLN تقريباً
بدون
لحان الى غرناة استن
Lymphosc.

زراعة (استن):

Hand-held ga
Counter & Vi

Inspect (f
Inspect

(Hot blue
SLN)

طريق

① H&E

② Immu
Histoch
(Sico & b

③ RT-PCR

So Any Tm > 1mm Thickness
Do Try Tm Excision +
Intraoperative SLND
(AJCC)
also if ulcerat
or Invisio.

What happens at follow-up?

The main purpose of follow-up is to detect recurrences early but it also offers an opportunity to diagnose a new primary melanoma at the first possible opportunity. A second invasive melanoma occurs in 5-10% patients; an unrelated melanoma in situ affects in more than 20% of melanoma patients. The Australian and New Zealand Guidelines for the Management of Melanoma (2008) make the following recommendations for follow-up for patients with invasive melanoma.

- Self skin examination
- Regular routine skin checks by patient's preferred health professional
- Follow-up intervals are preferably six-monthly for five years for patients with stage 1 disease, three-monthly or four-monthly for five years for patients with stage 2 or 3 disease, and yearly thereafter for all patients.
- Individual patient's needs should be considered before appropriate follow-up is offered
- Provide education and support to help patient adjust to their illness

The follow-up appointments may be undertaken by the patient's general practitioner or specialist or they may be shared.

Follow-up appointments may include:

- A check of the scar where the primary melanoma was removed
- A feel for the regional lymph nodes
- A general skin examination
- A full physical examination
- In those with many moles or atypical moles, baseline whole body imaging and sequential macro and dermoscopic images of melanocytic lesions of concern (mole mapping)

In those with more advanced primary disease, follow-up may include:

- Blood tests, including LDH
- Imaging: ultrasound, X-ray, CT, MRI and/or PET scan.


Tests are not typically worthwhile for stage 1/2 melanoma patients unless there are signs or symptoms of disease recurrence or metastasis. And no tests are thought necessary for healthy patients who have remained well for 5 years or longer after removal of their melanoma, whatever stage.

What is the outlook?

Melanoma in situ is not dangerous; it only becomes potentially life threatening if an invasive melanoma develops within it. The rates of melanoma in situ are not reported by cancer registries. The risk of spread and ultimate death from invasive melanoma depends on several factors, but the main one is the measured thickness of the melanoma at the time it was surgically removed.

The Melanoma Guidelines report that metastases are rare for melanomas <0.75mm and the risk for tumours 0.75–1 mm thick is about 5%. The risk steadily increases with thickness so that melanomas >4 mm have a risk of metastasis of about 40%.

New Zealand statistics gathered by the Cancer Registry between 1994 and 2004 revealed 15,839 invasive melanomas. Of these, 52% were under 0.75 mm in thickness, 22% were between 0.76 and 1.49 mm, 15% were between 1.5 and 3 mm in thickness and 11% were more than 3 mm in thickness. Thicker tumours were slightly more likely to be diagnosed in males, and more likely in older people than younger ones.



2. (NB) Limb perfusion:

- Circulation of affected limb is isolated → Blood slowly heated → Reinfused to the limb again i high doses of Melphalan or TNF α or IFN γ .
- when the limb circ. is isolated from the remaining systemic circ. → Much higher doses of therapeutic agents can be administered without marked systemic

2. Types of Mast cells: → (3) ← $\begin{matrix} C-T \\ \text{Mucosa} \end{matrix}$

Type	Type of Enzyme	
1. <u>T Type</u>	Tryptase	• Mucosa of $\begin{matrix} \text{GIT} \\ \text{RT} \end{matrix}$
2. <u>C Type</u>	Chymase	• <u>SKIN & L.N</u> (SL)
3. <u>TC Type</u>	Tryptase & Chymase	• SKIN & GIT (sub-mucosa) (ST)


3. Mast cells Stimuli (Secretagogues):

Mast cell secretagogues	
Immune stimuli	Non-Immune stimuli
<ul style="list-style-type: none"> • IgE-mediated • C3a, C4a, C5a, • IL1 • TNF (tumor necrosis factor) 	<ul style="list-style-type: none"> • Drugs (i.e. opiates) • Radiocontrast media • Physical stimuli (heat & irradiation) • Neuroenteric peptides

→ direct Histamine Liberators ??

- Aspirin
- Streptolysin
- Vancomycin
- C5

4. Mast cells Mediators:



• Tryptase & Chymase: + C3 $\begin{matrix} C3a \rightarrow ++ \text{ mast cells} \\ C3b \rightarrow ++ \text{ alternative C. pathway} \end{matrix}$

• Chymase: ++ Mast Cell degran.

5. Histamine Receptors: 4 Types

Receptor Type	Major Tissue Locations	Major Biologic Effects
H ₁	smooth muscle, endothelial cells • Broncho Constrictor, CNS	acute allergic responses → V.D. & permeability
H ₂	gastric parietal cells • Smooth MS.	secretion of gastric acid
H ₃	central nervous system : ↓ NE, ACh, Serotonin, ↓ Hist. (presynaptic autoregulation)	modulating neurotransmission
H ₄	mast cells, eosinophils, T cells, dendritic cells	regulating immune responses

Smooth muscle
↓
Bronchi
↓
Relaxation Contraction

NB Effects of release of Mediators & Cytokines : (فعلية خلية)

1. IL4

→ ++ B Cells → ↑ IgE

2. IL5 → ++ Eosinophils

3. IL6 → . ↑ IgE

• ++ TC growth & maturation

4. IL8 → ++ Neutrophils chemotaxis.

5. TNF-α → ++ All!

• Neut.


• Eos

• Fibroblast

• Phagocytosis.

Blood → Aggregated (macrophages, etc.)
Skin → aggregated.
القوى الجاذبة
Blood & Skin
Mast Cells?

الخلايا الحبيبية



Mast cell diseases

① Cut. immediate hypersensitivity React., urticaria (IgE)

② AD

③ Allergic CD

④ B-P

⑤ PS: ± develop d.t mast cell mediated vascular alterat.

⑥ PRV → Mast Cell → PG → (itching) Scleroderma

⑦ Fibrotic diseases

GVHD

PCT

Test T Cells →
Lymphokines
act on mast
cell then
mast cell → ++
fibrosis ELI

⑧ NF*

⑨ → Scars & Keloid

⑩ UVR → ++ Complement → Anaphylatoxins
↓

⑪ wound healing:

⑫ Histamine → Released

①. ++ Collagen Synth

②. ++ Vascular permeab.

③. Angiogenesis

④. ++ Fibroblast mitogenesis

⑤. Collagen Synth.

⑬ Mastocytosis

⑭ Necrotizing Vasculitis

Hypertrophic

Sp. Sp

Mastocytosis

updated
2017

Def. disorder cli B, Mast cell prolif. & Accumulat. within many organs, most commonly the skin.

Etiopathogenesis: Mast cells Express cell receptors called: c-Kit (CD117) receptors (or) are Rs for stem cell factor (SCF, its Ligand) w is important for Mast cell prolif. Mutatⁿ in c-Kit receptors → (uncontrolled) Stimulⁿ of receptors → prolif. & Accumulat. in various tiss.
Inhibiting Tyrosine Kinase receptor i Imatinib may treat mastocytosis.

Classification of Mastocytosis

3 classifications:

A. WHO Classification: (2001)

Cut. Mastocytosis (5)

Commonest in children

← Urticaria pigmentosa

Commonest in Adult.

← Maculopapular

Rare Types


- Diffuse cut.
- TMEP
- Mastocytoma
- Erythrodermic

Cut
Systemic ←
Mast cell leukaemia
" " Sarcoma
Extracut.

Systemic mastocytosis

- Indolent
- Aggressive
 - Mast cell leukemia
 - Mast cell sarcoma
- Ass. with clonal Hematological non Mast cell lineage dis. (AHNMD)
- Extracut. mastocytoma

• Age: 2 peaks:



Fat ↓
• 50% → resolut-
• 40% → reduct-
• 10% → persist.
at puberty

usually
persistent

75% of
Mastocytosis
cases occur
at infancy
or early
childhood

• Sex: M = F.

C/P of Mastocytosis

A

Symptoms of Mastocytosis:

① There may be: (more in Adult type)

- pruritus
- Flushing
- Abd. pain
- diarrhoea
- Palpitation
- dizziness
- Syncope
- Shock.

→ All are physiological

Effects of Histamine &
mast cell mediators release.

② If there are: Fever, wt loss, malaise, boneache,
Epigastric distress & Cognitive disorganization
indicating → Extracut. dis.

• Symptoms may be ppt by:

1. Exercise
2. Heat
3. Local Trauma
4. Alcohol

• Drugs:

- | | |
|---------------|-------------|
| • Alcohol | • Narcotics |
| • Salicylates | • systemic |
| • NSAIDs | anaesth. |

B

Cut. lesions of Mastocytosis:

الترتيب
81

Childhood Mastocytosis (<15y)

Adulthood (>15y)

1. Generalized → Maculopapular or UP
(60-90%)1. Generalized Maculopapular
Commonest2. Localized → Solitary Mastocytoma.
(15-20%)

2. TMEP

3. Diffuse Cut.

3. Diffuse Cut.

A. Childhood Mastocytosis:

1. urticaria pigmentosa (UP) (Childhood Generalized Maculopap. Mastocytosis). incd: Commonest Type affecting the children (60-90%). onset: Infancy (1st year). lesion: Maculopapular:

. Multiple, generalized, small

. reddish-brown

. usually on trunk (but may affect Head & Neck)

. on Rubbing → urticaria (Darier's

Sign) Followed by refractory period of (2-3 d).

. varieties ① Nodular
② Vesicular

③ Bullous UP. → bullae + UP lesions

④ Xanthasma UP → pale-yellow lesions

51

Bullous UP
&
Bullous
Mastocytosis
?

- Fate:
- 50% → resolve at puberty
 - 40% → +/−
 - 10% → persist

2. Localized Mastocytosis → Solitary Mastocytoma

- Incid: 15-20% of mastocytosis cases in children (2nd most common).
- onset: infancy or birth
- lesion: → Solitary Nodule: (± 2-3) nodules.
or plaque.
- Yellow-tan → "Dorsal Hand"
- usually on wrist but may be at Trunk & Neck.
- Rubbing → +ve Darier sign
& may be flushing or even shock
- involut: → ≈ 10Y.

3. Diffuse Cut. Mastocytosis: (Erythredemic or Xanthoplasmoid Mastocytosis)

- onset: infancy.
- lesion: Skin ch by: (3) -
- Hyperpig: → generalized, brownish-orange discoloration.
- Infiltration: → doughy or boggy sensation.
- Lichenification & "diffuse blistering".
- varieties: → diffuse cut. blistering may occur so called « Bullous Mastocytosis ».

(app. 5)

onset
All infancy

(1) UP: reddish-brown macule on Trunk → +ve Darier

varieties Fate:

(2) Solitary Mast: reddish brown

(1-3) Nodule at dorsal rest → +ve Darier. onset: resolve at: ✓

(3) Diffuse Cut:

- Infant
- Hyperpig
- Lichenified
- Bullous

B. Adulthood Mastocytosis:

(30-50%)

الفحص الجلدي

- Hyperpigment
- Telangiect
-ve Darier
persist

1. Generalized → Maculopapular Mastocytosis

• incid: Commonest Type in adults.

• lesion: reddish-brown macules & papules usually on Trunk & proximal Extremities.
(2) may show → Hyperpigment. & Telangiectasia.

• Fate: → usually persistent.

أحياناً تتركز في
الجلد
وغيره

"Paucicellular Mastocytosis" → 2. Telangiectasia Macularis Erythra Persians: (TMEP)

• incid: 2nd Commonest Type in adults.

• lesion: "yellowish"

Macules & patches with Telangiectasia & non significant Hyperpigment.

• Fate: resistant & persistent.

Darier
Sign:

barely
detectable.

3. Diffuse Cut. → as before but appears on adulthood.

	Childhood Mastocytosis	Adulthood Mastocytosis
• <u>Incid</u> :	More Common (75%)	less Common
• <u>lesion</u> :	Commonest Types: ① UP ② Mastocytoma.	Commonest types: ① Generalized Maculopapular ② TMEP.
• <u>Darier Sign</u> :	usually +ve	usually: -ve.
• <u>Systemic marks & signs</u> :	less Common	More Common.
• <u>Fate</u>	UP → ^{to} Pubert. (50%) Mastocytoma of <u>long</u> .	Persistent.

Histopathology of Cut. Mastocytosis:

أخذ العينات: الجلد

① Inject local anasth.

But < without epinephrin & around the lesion

all will → Mast Cell degranulation & -ve results

② avoid Trauma or Crushing of the specimen.

③ أخذ العينات من الجلد: جلد

Leder stain
detect mast cell granules.

④ Gramsa or TB to detect mast cell granules.

Results: Monoclonal antibodies against CD117 (detect mast cells)

at Papillary dermis
UP → Mast Cell ch-BY.
T. Blue → purple → Metachromatic granules
Nuclei are rounded with surrounding ample cytoplasm → Fried Egg appearance.

TMEP → Mast Cells are brick or spindle shaped.

Nodular up. → dense aggregate of Mast cells may affect entire dermis → S.C.T.

Diffuse Mastocytosis: dense, band like subepid; Mast Cell infilt.


Bullous Mastocytosis: subepid. bullae.

Lab. Inv. For Systemic Mastocytosis

① Serum Tryptase


③ BMA: if ↑ Tryptase HSM

② Urinary: Histamine, N-methyl histamine, N-methyl Imidazole acetal, PGD2



Systemic mastocytosis

WHO



WHO Criteria of Systemic Mastocytosis

- Major: Mast Cell infiltr — {
 - Multifocal
 - > 15 cells in aggregates
 - BM &/or extracut. affect
- Minor: > 25% of these 3 mast cells are — {
 - Spindle
 - or
 - Atypical
- Tryptase > 20 ng/ml
- A Codon 816 KIT Mutate
- Aberrant expression of CD25 &/or CD2

For diagnosis

1 J + 1 M or 3 minor.

Darier Sign

① +ve in 2 dis — mastocytosis
Leukemia cuti

② —ve in 'Adelhood mastocytosis'?

d.1 low concentration of infiltrating mast cells e.g

• Solitary mastocytoma : 140 fold

• Urticaria pigmentosa : 40 "

• Adult mastocytosis : 8 "

} The NL
Skin.

So — TMEP
Generalized
Adult mast.

Called ((Paucicellular mastocytosis))

Treatment

(Symptomatic; No Cure)

① Reassurance : in childhood Type

② Avoid mast cell degranulators

- Alcohol, Aspirin, NSAIDs, Narcotics & Systemic (Not local) Anaesthesia
- Heat, Friction

③ Local :

- Cs : Potent & Superpotent ; ± under occlusion
- IL Cs

④ Oral :

- Antihistamines (H₁ & H₂ blockers)
- Mast Cell Stabilizers
- Systemic Cs
- PUVA.

⑤ Aggressive (Systemic mastocytosis)

- Imatinib methylate or
- IFN-α2b.